Negative regulation of Plasma cells by CD28 and B7 molecules
CD28 和 B7 分子对浆细胞的负调控
基本信息
- 批准号:8513589
- 负责人:
- 金额:$ 44.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-15 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAffectAntibodiesAntibody FormationAntigensAsthmaAutoimmune DiseasesAutoimmunityBindingBird Flu vaccineBone MarrowCD28 geneCell Surface ProteinsCell physiologyCellsCellular biologyDataDiseaseEnhancing AntibodiesExhibitsExperimental Autoimmune EncephalomyelitisExposure toFeasibility StudiesHealthHumanImmune responseImmune systemImmunityInfectionInflammationInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H5N1 SubtypeInterruptionInvadedKnowledgeLeadLifeLigandsLongevityMediatingMediator of activation proteinModelingMultiple MyelomaMusPhenotypePlasma CellsPlayProductionPublished CommentReactive Plasma CellRegulationResearch ProposalsRoleSerologicalSerumSignal TransductionSmallpox VaccineSourceStressStromal CellsT-Cell ActivationT-LymphocyteTailTestingTimeVaccinesVietnamWorkbaseimmunogenicin vivoinfluenzavirusknockout geneneutralizing antibodypathogenresponseseasonal influenzasrc-Family Kinases
项目摘要
DESCRIPTION (provided by applicant): Exposure to pathogens leads to the sustained production of serum antibodies for a life-time. For instance, humans immunized with smallpox vaccine exhibit stable levels of neutralizing antibodies in their serum for over 75 years. Antibodies are produced by plasma cells and these cells are critical effectors of the humoral immune system both in health (responses to pathogens) and in disease (autoimmunity) and hence, it is important to better understand how these cells are regulated and maintained. CD28 is a cell surface protein that is critical for the activation of na¿ve T cells. Interestingly, CD28is expressed also on plasma cells and multiple myeloma cells. Here we provide evidence that CD28 is expressed on both short-lived as well as long-lived plasma cells in the bone marrow. Very little is known about the function of CD28 on plasma cells. We also demonstrate that short- and long-lived plasma cells also express the ligands for CD28, B7.1 and B7.2. Based upon our compelling preliminary data, our central hypothesis is that CD28/B7 molecules are critical for the regulation of plasma cell function and modulation of this interaction using soluble CD28 or B7 molecules will enhance immune responses in vivo. We will test our central hypothesis by pursuing three specific aims. We will determine the extent to which CD28 (Aim 1) and B7. /B7.2 (Aim 2) affects plasma cell function and longevity and determine whether soluble CD28 or B7 can be used to enhance host immune responses to poorly-immunogenic H5N1 avian influenza vaccine (Aim 3). The proposed work is significant, because upon completion, we will have a better understanding of how CD28 and or B7 molecules modulate function and longevity of plasma cells. This could potentially be used to (a) enhance vaccine-induced Ab responses or (b) down modulate self-reactive plasma cells in autoimmune disorders.
描述(由申请人提供):接触病原体会导致终生持续产生血清抗体,例如,接种天花疫苗的人在其血清中表现出稳定水平的中和抗体超过 75 年。浆细胞和这些细胞是健康(对病原体的反应)和疾病(自身免疫)中体液免疫系统的关键效应器,因此,更好地了解这些细胞的作用非常重要CD28 是一种细胞表面蛋白,对于 na¿ 的激活至关重要。提示,CD28也在浆细胞和多发性骨髓瘤细胞上表达,我们提供的证据表明CD28在骨髓中的短寿命和长寿命浆细胞上都表达,但对其功能知之甚少。我们还证明,短寿命和长寿命的浆细胞也表达 CD28、B7.1 和 B7.2 的配体。根据我们令人信服的初步数据,我们的中心假设是: CD28/B7 分子对于浆细胞功能的调节至关重要,并且使用可溶性 CD28 或 B7 分子调节这种相互作用将增强体内免疫反应,我们将通过追求三个特定目标来检验我们的中心假设。 CD28(目标 1)和 B7.2(目标 2)影响浆细胞功能和寿命,并确定可溶性 CD28 或 B7 是否可用于增强宿主对免疫原性较差的 H5N1 禽类的免疫反应。流感疫苗(目标 3)。这项工作意义重大,因为完成后,我们将更好地了解 CD28 和/或 B7 分子如何调节浆细胞的功能和寿命。诱导抗体反应或(b)下调自身免疫性疾病中的自身反应性浆细胞。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The CD28/B7 pathway: a novel regulator of plasma cell function.
CD28/B7 途径:浆细胞功能的新型调节剂。
- DOI:10.1007/978-1-4614-6217-0_8
- 发表时间:2024-09-14
- 期刊:
- 影响因子:0
- 作者:Modesta N. Njau;Joshy Jacob
- 通讯作者:Joshy Jacob
CD28-B7 interaction modulates short- and long-lived plasma cell function.
CD28-B7 相互作用调节短寿命和长寿命浆细胞功能。
- DOI:
- 发表时间:2012-09-15
- 期刊:
- 影响因子:0
- 作者:Njau, Modesta N;Kim, Jin Hyang;Chappell, Craig P;Ravindran, Rajesh;Thomas, Leela;Pulendran, Bali;Jacob, Joshy
- 通讯作者:Jacob, Joshy
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSHY JACOB其他文献
JOSHY JACOB的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSHY JACOB', 18)}}的其他基金
Somatic hypermutation and rescue from self-reactivity in Pre-B lymphocytes
Pre-B 淋巴细胞的体细胞超突变和自身反应的拯救
- 批准号:
10153689 - 财政年份:2020
- 资助金额:
$ 44.57万 - 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
- 批准号:
8704872 - 财政年份:2012
- 资助金额:
$ 44.57万 - 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
- 批准号:
8299339 - 财政年份:2012
- 资助金额:
$ 44.57万 - 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
- 批准号:
8534701 - 财政年份:2012
- 资助金额:
$ 44.57万 - 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
- 批准号:
9114473 - 财政年份:2012
- 资助金额:
$ 44.57万 - 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
- 批准号:
8704872 - 财政年份:2012
- 资助金额:
$ 44.57万 - 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
- 批准号:
8899425 - 财政年份:2012
- 资助金额:
$ 44.57万 - 项目类别:
相似国自然基金
模式识别受体通过调节脂质代谢影响中性粒细胞程序性死亡参与抗中性粒细胞胞浆抗体相关小血管炎发病机制的研究
- 批准号:
- 批准年份:2022
- 资助金额:53 万元
- 项目类别:面上项目
枕大池注射CD47抗体通过CD47-SIRPα信号通路对大鼠脑出血后小胶质细胞/巨噬细胞清除红细胞效率和继发性损伤的影响和机制
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
eIF3a通过自噬溶酶体途径影响FGL1单克隆抗体疗效的机制研究
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
MDSC通过IDO1-Kyn-AhR通路介导Treg分化影响泡型包虫病PD-1抗体疗效的机制研究
- 批准号:82160397
- 批准年份:2021
- 资助金额:34 万元
- 项目类别:地区科学基金项目
PD-L1抗体通过影响小鼠脂质代谢抑制性激素分泌的机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
A synthetic biology approach for tau post-translational modifications in AD
AD 中 tau 翻译后修饰的合成生物学方法
- 批准号:
10739891 - 财政年份:2023
- 资助金额:
$ 44.57万 - 项目类别:
Identifying differences in dynamics and residual structure of intrinsically disordered domains between monomer and fibers: using alpha-synuclein as a model
识别单体和纤维之间本质无序域的动力学和残余结构的差异:使用α-突触核蛋白作为模型
- 批准号:
10607325 - 财政年份:2023
- 资助金额:
$ 44.57万 - 项目类别:
Defining the autoimmune mechanisms driving human MOG antibody disease pathology
定义驱动人类 MOG 抗体疾病病理学的自身免疫机制
- 批准号:
10748070 - 财政年份:2023
- 资助金额:
$ 44.57万 - 项目类别:
SUPPORTING WHO ONCHOCERCIASIS ELIMINATION PROGRAMS: PROGRESSING A HIGHLY SENSITIVE AND ULTRA-SPECIFIC RAPID DIAGNOSTIC TEST TO COMMERCIALIZATION READINESS
支持世界卫生组织根除盘尾丝虫病计划:推进高度敏感和超特异性的快速诊断测试以做好商业化准备
- 批准号:
10697164 - 财政年份:2023
- 资助金额:
$ 44.57万 - 项目类别:
Developing and Automating an Extracellular Vesicle-Based Test for Early Detection of Hepatocellular Carcinoma
开发和自动化基于细胞外囊泡的测试以早期检测肝细胞癌
- 批准号:
10823687 - 财政年份:2023
- 资助金额:
$ 44.57万 - 项目类别: